This filing is procedural and does not change the near-term thesis. The key catalyst remains the Treeline merger closing, which is a condition to this divestiture. Monitor for LAB shareholder vote on both the mass cytometry sale and the Treeline merger, and for any regulatory updates. The modest $5M base consideration is not material to LAB's valuation.
Price Chart
Executive Summary
Standard BioTools (LAB) filed an 8-K/A on July 29, 2026, attaching the full Share and Asset Purchase Agreement for the sale of its mass cytometry business to Multiplex Bio Inc., as previously announced on July 28, 2026. The deal includes a $5M base purchase price (paid via promissory note) plus up to $5M in contingent additional consideration tied to a future Qualifying Exit by Multiplex Bio. The transaction is a procedural step in LAB's broader restructuring ahead of its transformative reverse merger with Treeline Biosciences, and its closing is conditioned on the Treeline merger closing substantially concurrently.
Key Financial Metrics
Key Facts
- LAB sells its mass cytometry business (CyTOF, Hyperion, Maxpar, Theia platforms) to Multiplex Bio Inc.
- Base purchase price of $5,000,000, paid via a promissory note (Base Seller Note), subject to working capital and other adjustments.
- Additional contingent consideration of $5,000,000 if Multiplex Bio achieves a Qualifying Exit (e.g., sale, IPO) within 10 years.
- Target Working Capital set at $4,727,000.
- Seller termination fee of $1,000,000.
- Outside Date for closing is June 30, 2027, with automatic extensions for stockholder approval or antitrust issues.
- Closing is conditioned on LAB stockholder approval and the concurrent closing of the Treeline merger.
- Non-compete restricts LAB from engaging in mass cytometry business for 3 years post-closing.
Financial Impact
Base purchase price of $5M (promissory note) plus up to $5M contingent additional consideration; deal is small relative to LAB's $311M market cap and the $2.5B Treeline merger.
Risk Factors
- Failure to obtain LAB stockholder approval for the mass cytometry sale or the Treeline merger.
- Failure to close the Treeline merger, which would prevent this divestiture from closing.
- Potential competing offers or regulatory delays extending beyond the Outside Date.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001140361-26-029965 |
| Document: 0001140361-26-029965-index-headers.html | 0001140361-26-029965 |
| Document: 0001140361-26-029965-index.html | 0001140361-26-029965 |
| Document: 0001140361-26-029965.txt | 0001140361-26-029965 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 29, 2026 9w ago | 425 | $0.8739 $0.6518 | ▼ −25.41% | ▼ −30.43% | $0.7300 (−16.47%) |
Jul 28, 2026 9w ago | Press Release | $0.7947 $0.6500 | ▼ −18.21% | ▼ −21.59% | $0.7300 (−8.14%) |
Jul 20, 2026 10w ago | 425 | $0.8500 $0.6845 | ▼ −19.47% | ▼ −23.59% | $0.7300 (−14.12%) |
Jul 20, 2026 10w ago | S-4 | $0.8500 $0.6845 | ▼ −19.47% | ▼ −23.59% | $0.7300 (−14.12%) |
Jun 8, 2026 16w ago | 425 | $0.8032 $0.8873 | ▲ +10.47% | ▲ +8.84% | $0.7300 (−9.11%) |
Jun 8, 2026 16w ago | 8-K | $0.8032 $0.8873 | ▲ +10.47% | ▲ +8.84% | $0.7300 (−9.11%) |
Jun 8, 2026 16w ago | Press Release | $0.8032 $0.8873 | ▲ +10.47% | ▲ +8.84% | $0.7300 (−9.11%) |
Apr 24, 2026 23w ago | 8-K | $0.9000 $1.09 | ▼ −21.11% | ▼ −16.15% | $0.7300 (+18.89%) |
Apr 21, 2026 23w ago | Press Release | $0.9600 $0.9900 | ▲ +3.13% | ▼ −1.79% | $0.7300 (−23.96%) |
Feb 24, 2026 31w ago | 8-K | $1.17 $0.9600 | ▲ +17.95% | ▲ +12.71% | $0.7300 (+37.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access